Sarepta Therapeutics Inc
SRPT21.570USD
+0.629+3.01%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
2.12BCap. mercado
9.01P/E TTM
Más Datos de Sarepta Therapeutics Inc Compañía
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Información de la empresa
Símbolo de cotizaciónSRPT
Nombre de la empresaSarepta Therapeutics Inc
Fecha de salida a bolsaJun 04, 1997
Fundada en2013
Director ejecutivoMr. Douglas S. (Doug) Ingram, Esq., J.D.
Número de empleados1372
Tipo de seguridadOrdinary Share
Fin del año fiscalJun 04
Dirección215 1st St Ste 415
CiudadCAMBRIDGE
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal02142-1213
Teléfono16172744000
Sitio Webhttps://www.sarepta.com/
Símbolo de cotizaciónSRPT
Fecha de salida a bolsaJun 04, 1997
Fundada en2013
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Cristin Rothfuss
Cristin Rothfuss
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
19.15K
+38.59%
Mr. Bilal Arif
Mr. Bilal Arif
Executive Vice President , Chief Technical Operations Officer
Executive Vice President , Chief Technical Operations Officer
16.42K
-16.76%
Ms. Deirdre Connelly
Ms. Deirdre Connelly
Independent Director
Independent Director
--
--
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.21M
+1.02%
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
390.31K
--
Dr. Louise Rodino-Klapac, Ph.D.
Dr. Louise Rodino-Klapac, Ph.D.
Executive Vice President, Chief Scientific Officer, Head of R&D
Executive Vice President, Chief Scientific Officer, Head of R&D
57.60K
+21.66%
Mr. Ian Michael Estepan
Mr. Ian Michael Estepan
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
45.59K
+0.22%
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Dr. Hans Lennart Rudolf Wigzell, M.D., Ph.D.
Independent Director
Independent Director
22.84K
-2.30%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
21.18K
-44.29%
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de abr
Divisa: USDActualizado: dom., 6 de abr
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
Por negocioUSD
Nombre
Ganancia
Proporción
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
1.64B
86.11%
Rest of World
150.25M
7.90%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
PMO Products
967.17M
50.85%
ELEVIDYS
820.79M
43.15%
collaboration and other
114.02M
5.99%
Estadísticas de accionistas
Actualizado: lun., 19 de may
Actualizado: lun., 19 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Accionistas
Accionistas
Proporción
Capital International Investors
9.22%
The Vanguard Group, Inc.
9.17%
BlackRock Institutional Trust Company, N.A.
9.06%
Capital Research Global Investors
6.17%
State Street Global Advisors (US)
4.14%
Other
62.25%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
42.91%
Investment Advisor/Hedge Fund
37.22%
Hedge Fund
9.45%
Individual Investor
4.42%
Research Firm
3.31%
Bank and Trust
1.10%
Pension Fund
1.10%
Sovereign Wealth Fund
1.09%
Venture Capital
0.33%
Participación institucional
Actualizado: lun., 20 de ene
Actualizado: lun., 20 de ene
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q1
1045
100.62M
102.55%
-5.73M
2024Q4
1057
102.62M
105.91%
-1.51M
2024Q3
1027
96.14M
100.83%
-6.90M
2024Q2
997
94.21M
99.66%
-1.44M
2024Q1
932
88.31M
94.10%
-6.68M
2023Q4
926
87.42M
93.47%
-6.42M
2023Q3
916
88.86M
95.27%
-4.43M
2023Q2
931
87.46M
93.91%
-4.38M
2023Q1
946
86.41M
92.84%
-2.26M
2022Q4
996
84.01M
95.72%
-10.12M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Capital International Investors
8.70M
8.96%
+2.44M
+38.95%
Dec 31, 2024
The Vanguard Group, Inc.
9.07M
9.34%
+117.52K
+1.31%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
8.94M
9.21%
+162.26K
+1.85%
Dec 31, 2024
Capital Research Global Investors
5.93M
6.11%
+49.00
+0.00%
Feb 28, 2025
State Street Global Advisors (US)
4.07M
4.19%
-200.90K
-4.70%
Dec 31, 2024
Janus Henderson Investors
4.33M
4.46%
-30.19K
-0.69%
Dec 31, 2024
Barry (Richard J)
3.18M
3.28%
+2.38K
+0.07%
Mar 10, 2025
Avoro Capital Advisors LLC
2.56M
2.63%
--
--
Dec 31, 2024
Wellington Management Company, LLP
2.07M
2.13%
-657.84K
-24.13%
Dec 31, 2024
Farallon Capital Management, L.L.C.
2.87M
2.95%
+285.10K
+11.05%
Dec 31, 2024
Ver más
ETFs relacionados
Actualizado: vie., 6 de jun
Actualizado: vie., 6 de jun
Nombre
Proporción
Global X Genomics & Biotechnology ETF
2.35%
First Trust NYSE Arca Biotechnology Index Fund
2.26%
iShares Neuroscience and Healthcare ETF
1.65%
Tema Neuroscience and Mental Health ETF
1.2%
WisdomTree BioRevolution Fund
0.92%
Harbor Human Capital Factor Unconstrained ETF
0.87%
SPDR S&P Biotech ETF
0.82%
VanEck Biotech ETF
0.74%
Invesco S&P MidCap 400 Pure Growth ETF
0.57%
Direxion Daily S&P Biotech Bull 3X Shares
0.54%
Ver más
Global X Genomics & Biotechnology ETF
Proporción2.35%
First Trust NYSE Arca Biotechnology Index Fund
Proporción2.26%
iShares Neuroscience and Healthcare ETF
Proporción1.65%
Tema Neuroscience and Mental Health ETF
Proporción1.2%
WisdomTree BioRevolution Fund
Proporción0.92%
Harbor Human Capital Factor Unconstrained ETF
Proporción0.87%
SPDR S&P Biotech ETF
Proporción0.82%
VanEck Biotech ETF
Proporción0.74%
Invesco S&P MidCap 400 Pure Growth ETF
Proporción0.57%
Direxion Daily S&P Biotech Bull 3X Shares
Proporción0.54%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
